Business
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using
About this update from 10x Genomics, Inc.
[{"type":"text","content":"\nCollaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling\n\n\n BRISBANE, Calif.--(BUSINESS WIRE)--\nCareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a strategic collaboration with 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, to establish ImmuneScape™, a multiomics research initiative designed by CareDx to elucidate the biology of transplant organ rejection and therapeutic response. Insights generated from this program are intended to support future clinical diagnostic development.\n\n\nCareDx will leverage 10x’s Xenium spatial and Chromium Flex single cell platforms for this initiative, which aims to generate high-resolution maps of the complex immune mechanisms underlying organ rejection associated with AMR and MVI. These data may help characterize disease origin and trajectory, as well as therapeutic response, laying the groundwork for future breakthroughs with potential to advance personalized transplant medicine.\n\n\n“This collaboration marks a meaningful step in advancing precision transplant care,” said John Hanna, President & CEO of CareDx. “By uniting CareDx’s clinical and diagnostic expertise with 10x Genomics’ transcriptomics technologies, we’re building upon a robust scientific foundation to drive future organ-health innovation across our diagnostic pipeline. Through ImmuneScape we aim to generate insights that translate transplant biology into high-value patient impact.”\n\n\nImmuneScape will build on CareDx’s ongoing efforts to deepen biological understanding in transplantation by mapping immune cell populations and pathways that distinguish mechanisms of disease origin and inform treatment selection, prognosis, and therapeutic response. CareDx recently introduced HistoMap™ Kidney, a tissue biopsy-based gene expression classifier designed to refine rejection subtyping and inform therapeutic management. The collaboration further extends this effort by examining how tissue-level immune architecture may correlate with clinical outcomes, including...